Castle biosciences inc.

Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company...Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. Get the latest Castle Biosciences Inc (CSTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.

Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically ...About Castle Biosciences. Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. …Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.

Castle Biosciences is a high growth, commercial stage molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and ...

The Company expects to double its current workforce in Pittsburgh by the end of 2023. May 22, 2023 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc ...Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental ...ARTOTEL GROUP is built from a tremendous passion in promoting local art and creative hospitality. With wide range of hotel brands, events, and merchandise, …Company Summary. Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle ...Castle Biosciences, Inc. (NASDAQ:NASDAQ:CSTL) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsCamilla Zuckero - Vice President,...

MyPath Melanoma has over 35,000 clinically resulted cases and 9 publications including validation to outcomes. DiffDx-Melanoma offers a neural network, artificial intelligence-designed algorithm with a low rate of intermediate results. The test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and ...

Castle Biosciences, Inc. 19.85. +0.47. +2.43%. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences ...

Order a test. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Get Castle Biosciences Inc. (CSTL) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...Live Chat Inc. is a tool you can use to interact with customers or clients on the internet. More and more, consumers are demanding and expecting immediate help from the companies they approach. This application enables you to engage with cu...Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings results on Sunday, November, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.13. The firm earned $23.48 million during the quarter, compared to the consensus estimate of $23.66 million.Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to ...

Vice President, Investor Relations & Corporate Affairs. See full bio. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.19 Feb 2022 ... Castle Biosciences, Inc., Friendswood, TX 77546, USA. 7 Department of Dermatology, University of Barcelona, IDIBAPS, 08007 Barcelona, Spain ...Castle Biosciences Customer Service Email: [email protected] Call: (412) 820-3050 Billing and Insurance Questions Email: [email protected] Call: 866-788-9007, option #3 For additional information about Castle Biosciences or TissueCypher testing, please go to: CastleTestInfo.com Contact us at: (412) 820-3050Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $29.59. The company’s 50 day moving average price is $16.38 and its 200-day moving …FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating ...Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to ...Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression.

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new ...Our new mailing address will be Castle Biosciences, Inc., 505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546. Stockholders may confirm our then-current mailing address by visiting our website at www.CastleBiosciences.com or by calling us at 1-866-788-9007.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …NEW YORK, Aug. 2, 2013 /PRNewswire/ -- Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the Summer Academy Meeting of the ...Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Castle Biosciences, Inc. (the “Registrant”) is filing this Registration Statement on Form S-1 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”). This Registration Statement relates to the public offering of securities ...“Castle delivered a strong start to the year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Building on our strength and momentum from 2022, we delivered significant test report volume and revenue growth in the first quarter, which was driven by continued execution on our short- and long-term strategies.Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company... Get the latest Castle Biosciences, Inc. (CSTL) stock news and headlines to help you in your trading and investing decisions.You are cordially invited to attend the 2021 annual meeting of stockholders (the “Annual Meeting”) of Castle Biosciences, Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on Thursday, June 10, 2021, at 11:00 a.m. (local time) at the San Luis Resort, Spa and Conference Center, 5222 Seawall Boulevard ...

A list of the latest Castle Biosciences Inc News - CSTL Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions.

NEW YORK, Aug. 2, 2013 /PRNewswire/ -- Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the Summer Academy Meeting of the ...

Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.FRIENDSWOOD, Texas- Jan. 13, 2021--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.April 04, 2022 04:05 PM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide ...FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its acquisition of AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics ...Includes 277 shares acquired on August 31, 2022, under Castle Biosciences' employee stock purchase plan. 2. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. 3. The RSU's vest in four equal annual installments beginning on December 9, 2023. 4. On December 10, …FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its ...Castle Biosciences, Inc. (NASDAQ:CSTL) posted its Q2 results on August 8, reporting a GAAP loss per share of $0.06, beating expectations by $0.70. Its revenue of $34.8 million climbed 52.9% year ...Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M. Friendswood-based diagnostics company Castle Biosciences Inc. (Nasdaq: CSTL) will acquire San Diego ...Hayward Pool Products Inc is a leading manufacturer of high-quality pool equipment, including pumps, filters, heaters, and cleaners. If you’re lucky enough to own one of their products, it’s important to keep it in good condition to ensure ...Castle Biosciences, Inc. Common Stock (CSTL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ...

Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental ...3 Castle Biosciences, Inc, Friendswood, Texas. 4 University of Rochester, Rochester, New York. 5 Icahn School of Medicine at Mount Sinai, New York, New York; Arkansas Dermatology Skin Cancer Center, Little Rock, Arkansas. 6 Oregon Health & Science University, Portland, Oregon.FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced upcoming presentations on ...Instagram:https://instagram. tellus app reviewstocks for under 50how much does one brick of gold costwhere to day trade Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... oreillys auto stock pricesmullen automotive stocks Jun 23, 2019 · Our History. Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology. We continue to focus on transforming disease management in areas of unmet clinical need through the development and marketing of ... Customer Service: 866-788-9007. CLINICIAN PORTAL. Customer Service: 866-788-9007 nasdaq ibkr Apr 5, 2022 · Castle Biosciences to acquire mental health testing co. AltheaDX in deal worth up to $140M. Friendswood-based diagnostics company Castle Biosciences Inc. (Nasdaq: CSTL) will acquire San Diego ... Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) ...